About

Epiminder is driven by the desire to find a solution for those living with epilepsy, to give them a greater sense of control over their condition and free them from the significant limitations and anxieties that come with epilepsy.

Epiminder is driven by the desire to find a solution for those living with epilepsy, to give them a greater sense of control over their disease and free them from the significant limitations and anxieties that come with epilepsy.

News

Australian epilepsy monitoring system Minder® designated as Breakthrough Device by US FDA

Australian medical device innovator Epiminder raises $16m and expands clinical trial for epilepsy monitoring device

Australian medical technology innovators Epiminder and Seer Medical collaborate on epilepsy seizure detection and forecasting

Epi-Minder appoints COO to lead execution of Minder™ — breakthrough device for epilepsy and seizure-related conditions

Australian medical device innovator Epi-Minder raises $18m to develop its breakthrough epilepsy monitoring device

Executive Team

Dr Rohan Hoare

Chief Executive Officer and Director
Rohan has extensive experience in medical devices both in large established med tech companies (St. Jude Medical, Cyberonics) and start-ups (EndoStim, Brainmatterz). He holds a PhD from Harvard and is an alumni of McKinsey & Co.

Prof Mark Cook AO

Chief Medical Officer
Director of Neurology at St. Vincent’s Hospital, Mark is an internationally-renowned neurologist specialising in the treatment of epilepsy. He has led first-in-human studies of implantable systems for seizure prediction and intracranial drug delivery.

Dr John Heasman

Chief Operating Officer
John has over 20 years’ experience in medical devices. He provides specialist expertise, operations management and leadership for global activities and teams.

Dr Tracy Cameron

VP Clinical & Regulatory
Tracy has extensive background in neuromodulation, with over 25 years specific experience in the design and execution of clinical trials. Tracy has been involved in a leadership role in both large medical technology companies and startups helping to bring 510K and PMA devices to market in the US and around the world.

Steven Ringo

VP Software & AI
Steven is a software & cloud services architect with 25 years’ experience in enterprise software and cloud computing. He brings experience from Amazon Web Services, Cochlear and ASX100 companies. He has founded three successful start-up businesses.

Toby McSweeney

Chief Technology Officer
Toby has over 20 years’ experience in taking novel Class II and Class III medical devices to market. With extensive experience in developing Active Implantables for small to large medical device companies, through to leading start-ups, to efficiently take new devices to clinical trials and commercial release.

Board of Directors

Philip Binns (Chair)

Vice President/General Manager, Agilent Technologies
Philip has more than 30 years experience leading organizations across the scientific and life science industries.  In 2008 Philip was appointed by the Federal Government to chair the Future Manufacturing Innovation Council and in 2012 served on the Prime Minister’s Manufacturing Task Force.  He is a board member of the Bionics Institute and is a National Councillor for the Australian Industry Group.  Philip is also an active investor and mentor in early stage technology based companies.

Robert Klupacs

Chief Executive Officer, Bionics Institute
He is an Australian registered patent attorney who has had a wide and successful career to date within both private and publicly traded companies as well as the academic arena. He is a Founder of 28 start-up companies. He is a highly experienced professional, with over 30 years’ corporate experience, uniquely experienced in translating and commercialising early stage intellectual property into commercial product or investable corporate vehicles.

Catherine Picard

VP Advanced Innovation & Strategic Investments
Catherine leads the Advanced Innovation team, which develops new concepts, technologies, therapies and solutions for the future of Cochlear. Prior to joining Cochlear she had 17 years at GE Healthcare in research management, the last 4 of which as General Manager. From 2005-2015 she had a range of senior management responsibilities at Sorin Group. Following the merger of Sorin and Cyberonics in 2015 to form LivaNova she had the role of VP Heart Failure and Head of R&D Council. She joined Cochlear in April 2017

Patricia O’Rourke

National CEO Hospital Division, St Vincent’s Health
Patricia has more than 20 years’ experience in the health care industry, including senior management and executive roles. Patricia currently serves as a Director on the Boards of St Vincent’s Institute of Medical Research, the GARVAN Institute, the Aikenhead Centre for Medical Discovery and holds key advisory committee roles in NSW and Victoria. Patricia is a graduate of the Australian Institute of Company Directors and a graduate of the Harvard leadership program.

Mark Phelps

Vice President Customer Software Development
Mark leads the global Customer Software team at Cochlear, developing regulated medical device software and connected health solutions for patients and hearing care professionals. Mark has around 30 years experience, working globally across multiple industries in the areas of software, corporate and business development (M&A/CVC), business strategy and planning, and strategic program execution. Mark has spent the last 16 years in the medical device industry with Cochlear, and before that worked in sectors including investment banking, financial services, travel and transport.

Our Partners

Contact us